Enteric-coated Mycophenolate Sodium therApy versus cyclophosphamide for induction of Remission in Microscopic PolyAngiitis (EMSAR-MPA trial): study protocol for a randomised controlled trial
This study will evaluate the efficacy and safety of EC-MPS combined with glucocorticoid in patients with active and non-life-threatening microscopic polyangiitis (MPA).
Methods and analysis
This study is a multicentre, open-label, randomised controlled, non-inferiority trial. A total of 110 patients with active and non-life-threatening MPA from 11 hospitals in Shanxi Province of China will be recruited and randomised in a 1:1 ratio to receive either EC-MPS or CYC. All patients will receive the same glucocorticoid plan. We will compare oral EC-MPS (720–1440 mg/day) with intravenous pulsed CYC (7.5–15 mg/kg) adm...
Source: BMJ Open - March 11, 2024 Category: General Medicine Authors: Li, S., Yao, S., Tie, X., Shi, X., Feng, R., Su, X., Wang, L. Tags: Open access, Immunology (including allergy) Source Type: research
The role of BAFF and BAFF-R inhibitors in the treatment of immune thrombocytopenia; a focused review
Int Immunopharmacol. 2024 Mar 8;131:111827. doi: 10.1016/j.intimp.2024.111827. Online ahead of print.ABSTRACTImmune thrombocytopenia (ITP) is an autoimmune-driven disease characterized by increased destruction and impaired platelet production resulting in an enhanced risk of bleeding. Immunosuppressant agents are the most common treatment strategies for ITP. Despite their efficacy, these medications often cause unpredictable side effects. Recent investigations revealed that patients with ITP exhibit elevated B-cell activating factor (BAFF) levels in both their spleens and serum. Belimumab, a BAFF inhibitor, illustrated a p...
Source: International Immunopharmacology - March 9, 2024 Category: Allergy & Immunology Authors: Mohammad Ali Nilforoushzadeh Nazila Heidari Amirhossein Heidari Yekta Ghane Zahra Lotfi Fariba Jaffary Minou Najar Nobari Niloufar Najar Nobari Source Type: research
The role of BAFF and BAFF-R inhibitors in the treatment of immune thrombocytopenia; a focused review
Int Immunopharmacol. 2024 Mar 8;131:111827. doi: 10.1016/j.intimp.2024.111827. Online ahead of print.ABSTRACTImmune thrombocytopenia (ITP) is an autoimmune-driven disease characterized by increased destruction and impaired platelet production resulting in an enhanced risk of bleeding. Immunosuppressant agents are the most common treatment strategies for ITP. Despite their efficacy, these medications often cause unpredictable side effects. Recent investigations revealed that patients with ITP exhibit elevated B-cell activating factor (BAFF) levels in both their spleens and serum. Belimumab, a BAFF inhibitor, illustrated a p...
Source: International Immunopharmacology - March 9, 2024 Category: Allergy & Immunology Authors: Mohammad Ali Nilforoushzadeh Nazila Heidari Amirhossein Heidari Yekta Ghane Zahra Lotfi Fariba Jaffary Minou Najar Nobari Niloufar Najar Nobari Source Type: research
Rituximab ‐induced psoriasis in a patient with pemphigus vulgaris: A case report and literature review
Key Clinical MessageRituximab which is established as a main treatment for pemphigus vulgaris can be a potential causative factor for development of psoriasis in some patients. It is preferred to avoid using rituximab in patients who had a history of psoriasis. Acquainting medical doctors about rituximab-related cutaneous complications will help them in detection and management.AbstractRituximab is a human/murine monoclonal antibody targeting the CD20 antigen on B-lymphocytes surface. Although it is used as promising treatment for pemphigus, nowadays it is also a new therapy for other autoimmune diseases including systemic...
Source: Clinical Case Reports - March 9, 2024 Category: General Medicine Authors: Leila Ghadirzade Arani,
Shima Moslemi Haghighi,
Soheila Nasiri,
Sahar Dadkhahfar Tags: CASE REPORT Source Type: research
Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group
This study was registered with ClinicalTrials.gov on Aug 4th, 2009, number NCT00954005. (Source: Annals of Hematology)
Source: Annals of Hematology - March 9, 2024 Category: Hematology Source Type: research
A single ‐centre, real‐world study of BTK inhibitors for the initial treatment of MYD88mut/CD79Bmut diffuse large B‐cell lymphoma
ConclusionThis study suggests that newly diagnosed DLBCL patients with MYD88mut and/or CD79Bmut may benefit from BTKis according to real-world clinical data. (Source: Cancer Medicine)
Source: Cancer Medicine - March 8, 2024 Category: Cancer & Oncology Authors: Ting Deng,
Shiyuan Zhang,
Min Xiao,
Jia Gu,
Liang Huang,
Xiaoxi Zhou Tags: RESEARCH ARTICLE Source Type: research
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for Bruton's tyrosine kinase inhibitors (BTKis) single and its combination therapy
CONCLUSIONS: The Ibrutinib-Obinutuzumab combo has the highest risk of infection, atrial fibrillation and myelosuppression, the Ibrutinib-Lenalidomide combo has the highest risk of pyrexia. However, the Ibrutinib-Venetoclax combo has a lower risk of hemorrhage than monotherapy.PMID:38456691 | DOI:10.1080/14740338.2024.2327507 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - March 8, 2024 Category: Drugs & Pharmacology Authors: Sichun Xiang Rongbin Shen Jingjing Xiang Ni Zhu Jianyou Gu Jianping Shen Yu Zhang Hangping Ge Source Type: research
A single-centre, real-world study of BTK inhibitors for the initial treatment of MYD88 < sup > mut < /sup > /CD79B < sup > mut < /sup > diffuse large B-cell lymphoma
CONCLUSION: This study suggests that newly diagnosed DLBCL patients with MYD88mut and/or CD79Bmut may benefit from BTKis according to real-world clinical data.PMID:38457222 | DOI:10.1002/cam4.7005 (Source: Cancer Control)
Source: Cancer Control - March 8, 2024 Category: Cancer & Oncology Authors: Ting Deng Shiyuan Zhang Min Xiao Jia Gu Liang Huang Xiaoxi Zhou Source Type: research
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for Bruton's tyrosine kinase inhibitors (BTKis) single and its combination therapy
CONCLUSIONS: The Ibrutinib-Obinutuzumab combo has the highest risk of infection, atrial fibrillation and myelosuppression, the Ibrutinib-Lenalidomide combo has the highest risk of pyrexia. However, the Ibrutinib-Venetoclax combo has a lower risk of hemorrhage than monotherapy.PMID:38456691 | DOI:10.1080/14740338.2024.2327507 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - March 8, 2024 Category: Drugs & Pharmacology Authors: Sichun Xiang Rongbin Shen Jingjing Xiang Ni Zhu Jianyou Gu Jianping Shen Yu Zhang Hangping Ge Source Type: research
Autoimmune nodopathy with anti-contactin 1 antibody characterized by cerebellar dysarthria: a case report and literature review
ConclusionApart from peripheral neuropathies, cerebellar dysarthria (central nervous system involvement) should not be ignored in AN patients with CNTN1 antibodies. (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - March 8, 2024 Category: Allergy & Immunology Source Type: research
An updated management approach of Pompe disease patients with high-sustained anti-rhGAA IgG antibody titers: experience with bortezomib-based immunomodulation
DiscussionThese case studies and our previous experience suggest that to achieve an effective reduction of anti-rhGAA antibodies in the setting of HSAT, bortezomib should be initiated at the earliest sign of high anti-rhGAA antibodies with a minimum of two consecutive cycles as shown in the case of patient 8. It is important to note that, despite initiation of ERT at age 2.3 weeks, patient 8 quickly developed HSAT. We recommend close monitoring of anti-rhGAA antibodies and early intervention with ITI as soon as significantly elevated anti-rhGAA antibody titers are noted. (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - March 8, 2024 Category: Allergy & Immunology Source Type: research
Optimal course of pre-emptive rituximab administration for long-term disease remission in patients with complicated steroid-dependent nephrotic syndrome requiring immunosuppressive agents after rituximab
(Source: Clinical and Experimental Nephrology)
Source: Clinical and Experimental Nephrology - March 8, 2024 Category: Urology & Nephrology Source Type: research
Combination treatment with rituximab and belimumab in shrinking lung syndrome in systemic lupus erythematosus
(Source: International Journal of Rheumatic Diseases)
Source: International Journal of Rheumatic Diseases - March 7, 2024 Category: Rheumatology Authors: Adriana C. Esteves,
Beatriz Mendes,
Helena Assun ção,
Luís S. Inês Tags: LETTER TO THE EDITOR Source Type: research
